Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 2
1984 2
1985 1
1986 1
1987 1
1988 4
1989 5
1990 2
1991 1
1992 5
1993 7
1994 12
1995 12
1996 11
1997 24
1998 17
1999 23
2000 15
2001 16
2002 13
2003 18
2004 13
2005 17
2006 11
2007 19
2008 24
2009 18
2010 17
2011 11
2012 19
2013 28
2014 31
2015 30
2016 13
2017 11
2018 9
2019 3
2020 10
2021 10
2022 13
2023 22
2024 13

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

488 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean t ishizaki[Author] (1,509 results)?
Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial.
Takeda T, Asaoka D, Nojiri S, Yanagisawa N, Nishizaki Y, Osada T, Koido S, Nagahara A, Katsumata N, Odamaki T, Xiao JZ, Ohkusa T, Sato N. Takeda T, et al. Among authors: nishizaki y. Am J Gastroenterol. 2023 Mar 1;118(3):561-568. doi: 10.14309/ajg.0000000000002028. Epub 2022 Oct 3. Am J Gastroenterol. 2023. PMID: 36216361 Free PMC article. Clinical Trial.
Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study.
Nishizaki Y, Miyauchi K, Iwata H, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H. Nishizaki Y, et al. Am Heart J. 2023 Mar;257:1-8. doi: 10.1016/j.ahj.2022.11.008. Epub 2022 Nov 11. Am Heart J. 2023. PMID: 36372250 Free article.
Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).
Miyauchi K, Iwata H, Nishizaki Y, Inoue T, Hirayama A, Kimura K, Ozaki Y, Murohara T, Ueshima K, Kuwabara Y, Tanaka-Mizuno S, Yanagisawa N, Sato T, Daida H; RESPECT-EPA Investigators. Miyauchi K, et al. Among authors: nishizaki y. Circulation. 2024 Aug 6;150(6):425-434. doi: 10.1161/CIRCULATIONAHA.123.065520. Epub 2024 Jun 14. Circulation. 2024. PMID: 38873793 Clinical Trial.
OX40/OX40 ligand and its role in precision immune oncology.
Thapa B, Kato S, Nishizaki D, Miyashita H, Lee S, Nesline MK, Previs RA, Conroy JM, DePietro P, Pabla S, Kurzrock R. Thapa B, et al. Among authors: nishizaki d. Cancer Metastasis Rev. 2024 Sep;43(3):1001-1013. doi: 10.1007/s10555-024-10184-9. Epub 2024 Mar 25. Cancer Metastasis Rev. 2024. PMID: 38526805 Free PMC article. Review.
The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by specific antibodies, and immune-stimulatory molecules, such as T-cell co-stimulatory receptors that belong to the tumor necr …
The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhi …
Viewing the immune checkpoint VISTA: landscape and outcomes across cancers.
Nishizaki D, Kurzrock R, Miyashita H, Adashek JJ, Lee S, Nikanjam M, Eskander RN, Patel H, Botta GP, Nesline MK, Pabla S, Conroy JM, DePietro P, Sicklick JK, Kato S. Nishizaki D, et al. ESMO Open. 2024 Apr;9(4):102942. doi: 10.1016/j.esmoop.2024.102942. Epub 2024 Mar 18. ESMO Open. 2024. PMID: 38503143 Free PMC article.
Herein, we analyzed the transcriptomic expression and clinical correlates of V-domain immunoglobulin suppressor of T-cell activation (VISTA), a promising targetable checkpoint. PATIENTS AND METHODS: RNA sequencing was carried out on 514 tissues reflecting diverse advanced/ …
Herein, we analyzed the transcriptomic expression and clinical correlates of V-domain immunoglobulin suppressor of T-cell activation …
Rosai-Dorfman disease with extranodal involvement.
Hashimoto K, Kariya S, Onoda T, Ooue T, Yamashita Y, Naka K, Okano M, Nishizaki K. Hashimoto K, et al. Among authors: nishizaki k. Laryngoscope. 2014 Mar;124(3):701-4. doi: 10.1002/lary.24290. Epub 2013 Jul 29. Laryngoscope. 2014. PMID: 23818241 Review.
The role of acyl-glucose in anthocyanin modifications.
Sasaki N, Nishizaki Y, Ozeki Y, Miyahara T. Sasaki N, et al. Among authors: nishizaki y. Molecules. 2014 Nov 14;19(11):18747-66. doi: 10.3390/molecules191118747. Molecules. 2014. PMID: 25405291 Free PMC article. Review.
Extended Polymorphism of Two-Dimensional Material.
Yoshida M, Ye J, Zhang Y, Imai Y, Kimura S, Fujiwara A, Nishizaki T, Kobayashi N, Nakano M, Iwasa Y. Yoshida M, et al. Among authors: nishizaki t. Nano Lett. 2017 Sep 13;17(9):5567-5571. doi: 10.1021/acs.nanolett.7b02374. Epub 2017 Aug 11. Nano Lett. 2017. PMID: 28777578
488 results